安捷伦将以9.5亿美元收购Biocare Medical，扩大病理学产品组合

2026-03-09 15:08

Agilent Technologies (A) has entered into a definitive agreement to acquire Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners LLP in an all-cash transaction valued at $950 million.
The deal is expected to be accretive to Agilent’s top-line growth rate, margin profile, and non-instrument revenue mix in year 1.
With more than 300 specialized antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025.
“The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation,” said Agilent President and CEO Padraig McDonnell.
The deal is expected to close by no later than Agilent's (A) fourth fiscal quarter of 2026. Upon close, Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group.

More on Agilent Technologies